Blueprint
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________
 
FORM 8-K
_____________
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
 
Date of report (Date of earliest event reported): November 7, 2016
 
 
 
TG Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
 
 
 
 
Delaware
(State or Other Jurisdiction
of Incorporation)
                001-32639
                (Commission File Number)
 
36-3898269
(IRS Employer Identification No.)
 
 
 
2 Gansevoort Street, 9th Floor
New York, New York 10014
(Address of Principal Executive Offices)
 
(212) 554-4484
(Registrant's telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
       ☐
Written communications pursuant to Rule 425 under the Securities Act.
       ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
       ☐
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
       ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
 
 
 
 
Item 2.02. Results of Operations and Financial Condition.
 
On November 7, 2016, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the third quarter ended September 30, 2016. TG also announced that on Monday, November 7, 2016 at 8:30am ET, TG would host an investor conference call during which the Company would provide a brief overview of its third quarter financial results and provide a business outlook for the remainder of 2016. A copy of such press release is being furnished as Exhibit 99.1.
 
Item 9.01 Financial Statements And Exhibits.
 
(d)          Exhibits.
99.1  
Press release issued by TG Therapeutics, Inc., dated November 7, 2016.
 
 
- 2 -
 
 
            SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
                                       TG Therapeutics, Inc.
                                       (Registrant)
 
                                                                                                                                               By: /s/ Sean A. Power       
                                                                                                                                               Sean A. Power
                                                                                                                                               Chief Financial Officer
 Date: November 7, 2016
 
 
- 3 -
 
 
                                                                                                     INDEX TO EXHIBITS
 
 
Exhibit
Number                   Description
 
99.1                          Press release issued by TG Therapeutics, Inc., dated November 7, 2016.
 
 
- 4 -